Urogen Pharma (NASDAQ: URGN) and Tyme Technologies (NASDAQ:TYME) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.
Institutional & Insider Ownership
32.6% of Urogen Pharma shares are owned by institutional investors. Comparatively, 2.5% of Tyme Technologies shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Urogen Pharma and Tyme Technologies’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Urogen Pharma||$17.53 million||39.72||-$1.94 million||N/A||N/A|
|Tyme Technologies||N/A||N/A||-$15.20 million||($0.17)||-20.06|
Urogen Pharma has higher revenue and earnings than Tyme Technologies.
This is a summary of recent ratings and price targets for Urogen Pharma and Tyme Technologies, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Urogen Pharma presently has a consensus price target of $42.80, indicating a potential downside of 15.48%. Tyme Technologies has a consensus price target of $8.25, indicating a potential upside of 141.94%. Given Tyme Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe Tyme Technologies is more favorable than Urogen Pharma.
This table compares Urogen Pharma and Tyme Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Urogen Pharma beats Tyme Technologies on 6 of the 8 factors compared between the two stocks.
About Urogen Pharma
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.
About Tyme Technologies
Tyme Technologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. The Company’s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and it is preparing to initiate an additional Phase II clinical trial for pancreatic cancer. The Company provides a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers including breast, lung, prostate, gastric, esophageal and pancreatic cancers.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.